8
Participants
Start Date
March 30, 2021
Primary Completion Date
April 15, 2023
Study Completion Date
April 15, 2023
Nivolumab and Intensity Modulated Radiotherapy (IMRT)
"Every included patient will receive the experimental treatment regimen as follows:~* Combination of IMRT 66 Gray (Gy)/24 fractions of 2.75 Gy) and immunotherapy with 3 doses of nivolumab, 240 mg (1th, 3th and 5th week of IMRT) during 5 weeks~* Maintenance treatment by nivolumab 240 mg (Q2W) during 6 months, or until progression and severe toxicity leading to definitive treatment interruption."
Centre de Lutte Contre le Cancer François Baclesse, Caen
Valérie JOLAINE, Rennes
Institut de Cancérologie de l'Ouest, Saint-Herblain
Centre Hospitalier de Brest, Brest
Centre de Lutte contre le Cancer Oscar Lambret, Lille
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Center Eugene Marquis
OTHER